Notable Labs, Ltd. (NASDAQ:NTBL) filed its Q3 2023 Form 10-Q, reporting financial results for the period ended September 30, 2023. The report includes pre-merger financials of VBL Therapeutics. Post-merger, Notable Labs had $14.3M in cash and equivalents as of October 31, 2023. The company, now trading under NTBL, is advancing its PPMP platform and cancer therapies, including Volasertib for AML. Additional financial details will be provided in a Form 8-K later in November. Phase 2a trial results for Fosciclopirox in AML patients are expected before the end of 2023.